ZBTB17

Across TCGA pan-cancer cohorts, ZBTB17 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ZBTB17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ZBTB17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZBTB17 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

HNSC, KIRC, and LIHC are the cancer types where ZBTB17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZBTB17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+0.810	<.001	12	view →
KIRC	Female	All	+0.587	<.001	11	view →
LIHC	Female	II,III,IV	+1.235	<.001	9	view →
THCA	All	All	−0.187	<.001	9	view →
BLCA	All	All	+0.523	<.001	8	view →
STAD	All	II,III,IV	+0.632	<.001	6	view →
UCEC	All	III,IV	+0.468	.013	6	view →
CHOL	Male	All	+1.613	<.001	5	view →
COAD	All	All	+0.289	.001	5	view →
KICH	All	All	−0.550	<.001	4	view →
ESCA	All	All	+0.339	.015	4	view →
LUSC	Male	III,IV	+0.522	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ZBTB17–HNSC

Open the HNSC breakdown →